Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
Atopic dermatitis (AD) is a chronic, pruritic skin disease often complicated by bacterial superinfection affecting 10.7% of American children. The pathogenesis involves a skin barrier breakdown in addition to dysfunctional innate and adaptive immune response, including an unbalanced increase in T-he...
Saved in:
Main Authors: | Rachael C. Saporito (Author), David J. Cohen (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2016-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis
by: Mahreen Ameen, et al.
Published: (2024) -
Efficacy of dupilumab in moderate and severe atopic dermatitis
by: Stephan Weidinger, et al.
Published: (2023) -
Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
by: Maria Esposito, MD, et al.
Published: (2023) -
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
by: Gisondi P, et al.
Published: (2016) -
Association of moderate-severe atopic dermatitis with dental anomalies
by: Sean Y Tan, et al.
Published: (2022)